Insomnia therapeutic - Blake Insomnia Therapeutics

Drug Profile

Insomnia therapeutic - Blake Insomnia Therapeutics

Alternative Names: Zleepax; ZLX-1

Latest Information Update: 15 Feb 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Zleepax
  • Developer Blake Insomnia Therapeutics
  • Class Antihypertensives; Small molecules
  • Mechanism of Action Beta 1 adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Insomnia

Most Recent Events

  • 02 Mar 2017 Blake Insomnia Therapeutics and Sajo Consulting plan clinical trials for Insomnia in Canada
  • 09 Feb 2017 Blake Insomnia Therapeutics and Sajo Consulting agree to co-promote and co-develop Zleepax™ for Insomnia
  • 09 Feb 2017 Blake Insomnia Therapeutics announces intention to submit NDA to Health Canada in second quarter of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top